S100A7 and bladder transitional cell carcinoma: revealed that S100A7 can shape an immunosuppressive TME and decrease the efficacy of immunotherapy in LUSC.[64] However, the expression patterns and functions of S100 proteins are cancer specific.[60] Regarding BLCA, only Yao et al.